Safety and clinical efficacy outcomes from the Long-term extension study of tolebrutinib in patients with relapsing multiple sclerosis: 2-year results

被引：0
|
作者：
Oh, J. [1 ]
Syed, S. [2 ]
Orogun, L. [2 ]
Xu, Z. [3 ]
Turner, T. J. [2 ]
Fox, R. J. [4 ]
机构：
[1] Univ Toronto, St Michaels Hosp, Toronto, ON, Canada
[2] Sanofi, Cambridge, MA USA
[3] Sanofi, Bridgewater, MA USA
[4] Cleveland Clin, Mellen Ctr Multiple Sclerosis, Cleveland, OH USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2022年 / 28卷 / 3_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P308
引用
收藏
页码：342 / 343
页数：2
相关论文
共 50 条
  • [1] MRI Outcomes from the Long-term Extension Study of Tolebrutinib in Patients with Relapsing Multiple Sclerosis: 2-Year Results
    Reich, Daniel
    Traboulsee, Anthony
    Syed, Sana
    Xu, Zhixing
    Turner, Timothy
    Arnold, Douglas
    NEUROLOGY, 2023, 100 (17)
  • [2] MRI outcomes from the long-term extension study of tolebrutinib in patients with relapsing multiple sclerosis: 2-year results
    Reich, D. S.
    Traboulsee, A.
    Syed, S.
    Xu, Z.
    Turner, T. J.
    Arnold, D. L.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 334 - 335
  • [3] Safety and Clinical Efficacy Outcomes From the Long-term Extension Study of Tolebrutinib in Participants With Relapsing Multiple Sclerosis: 2.5-Year Results
    Oh, Jiwon
    Syed, Sana
    Li, Tong
    Salloum, Naji
    Turner, Timothy J.
    Fox, Robert J.
    NEUROLOGY, 2023, 100 (17)
  • [4] Safety and Clinical Efficacy Outcomes from the Long-term Extension Study of Tolebrutinib in Participants with Relapsing Multiple Sclerosis: 3-Year Results
    Oh, Jiwon
    Reich, Daniel
    Traboulsee, Anthony
    Arnold, Douglas L.
    Syed, Sana
    Dukovic, Deborah
    Vargas, Wendy S.
    Turner, Timothy
    Fox, Robert J.
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 334 - 335
  • [5] Safety and Efficacy of Tolebrutinib from the Long-term Extension Study in Relapsing Multiple Sclerosis: 2.5-Year Results
    Oh, J.
    Syed, S.
    Li, T.
    Salloum, N.
    Turner, T.
    Fox, R.
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 642 - 643
  • [6] Safety and efficacy outcomes from the long-term extension study of tolebrutinib in patients with relapsing MS: Year 1 results
    Oh, J.
    Syed, S.
    Orogun, L.
    Matta, A.
    Dukovic, D.
    Fox, R.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 571 - 572
  • [7] MRI Outcomes from the Long-term Extension Study of Tolebrutinib in Participants with Relapsing Multiple Sclerosis: 3-Year Results
    Reich, Daniel
    Traboulsee, Anthony
    Oh, Jiwon
    Fox, Robert J.
    Syed, Sana
    Dukovic, Deborah
    Turner, Timothy
    Arnold, Douglas L.
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 592 - 592
  • [8] MRI outcomes from the long-term extension study of tolebrutinib in relapsing MS: Year 1 results
    Reich, D. S.
    Traboulsee, A.
    Syed, S.
    Dukovic, D.
    Turner, T.
    Arnold, D. L.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 571 - 571
  • [9] MRI, Safety, and Efficacy Outcomes in Patients with Relapsing MS: 18-month Results from the Long-term Extension Study of Tolebrutinib
    Oh, J.
    Fox, R.
    Arnold, D. L.
    Syed, S.
    Orogun, L.
    Dukovic, D.
    Turner, T.
    Traboulsee, A.
    Reich, D.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (1_SUPPL) : 66 - 67
  • [10] Long-term safety and efficacy of teriflunomide in patients with relapsing multiple sclerosis: Results from the TOWER extension study
    Miller, Aaron E.
    Olsson, Tomas P.
    Wolinsky, Jerry S.
    Comi, Giancarlo
    Kappos, Ludwig
    Hu, Xueqiang
    Xu, Xianhao
    Lublin, Alex L.
    Truffinet, Philippe
    Chavin, Jeffrey
    Delhay, Jean-Luc
    Benamor, Myriam
    Purvis, Annie
    Freedman, Mark S.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 46
12345